Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma - Concepedia

Concepedia

Publication | Closed Access

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

216

Citations

39

References

2009

Year

Raphaël Maréchal, John R. Mackey, Raymond Lai, Pieter Demetter, Marc Peeters, Marc Polus, Carol E. Cass, James D. Young, Isabelle Salmon, Jacques Devière,

Clinical Cancer Research

Abstract

Pancreatic adenocarcinoma patients with a high expression of hENT1 and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. These biomarkers deserve prospective evaluation in patients receiving gemcitabine-based adjuvant therapy.

References

	Year	Citations

Page 1